Patents by Inventor Amy J. Karlsson

Amy J. Karlsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Histatin-5 based synthetic peptides and uses thereof
    Patent number: 10464977
    Abstract: Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: November 5, 2019
    Assignees: University of Maryland, Baltimore, University of Maryland, College Park
    Inventors: Mary Ann Jabra-Rizk, Amy J. Karlsson, Svetlana Pavlova Ikonomova
  • Histatin-5 Based Synthetic Peptides and Uses Thereof
    Publication number: 20170291930
    Abstract: Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiologica condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
    Type: Application
    Filed: April 11, 2017
    Publication date: October 12, 2017
    Applicants: University of Maryland, Baltimore, University of Maryland, College Park
    Inventors: Mary Ann Jabra-Rizk, Amy J. Karlsson, Svetlana Pavlova Ikonomova
  • Beta-peptides with antifungal activity
    Patent number: 9168329
    Abstract: The present invention is directed to the design, synthesis and use of various ?-peptides exhibiting antifungal activity. The ?-peptides are relatively short in length, adopt globally amphiphilic conformations, and cause little lysis of human red blood cells at concentrations that kill Candida albicans, a common human fungal pathogen.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: October 27, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Sean P. Palecek, Samuel H. Gellman, William C. Pomerantz, Amy J. Karlsson